Hologic appoints new CEO
This article was originally published in Clinica
Robert Cascella has been named as CEO of Hologic. He will succeed Jack Cumming, who remains chairman and a member of the executive management team. Mr Cascella joined the company in February 2003 as chief operating officer, and was promoted to president in September 2003. Before this he had been a managing partner of CFG Capital, an investment banking firm specialising in healthcare, since 1998. Bedford, Massachusetts-based Hologic markets in vitro diagnostics for cervical cancer screening, preterm birth and prenatal genetic analysis, as well as imaging systems for breast cancer and osteoporosis, and other women's health products.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.